Status:
RECRUITING
Observational Study of Triple Combination Therapy of Zemidapa Tab. and Metformin in Type 2 Diabetes Mellitus Patients
Lead Sponsor:
LG Chem
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
19+ years
Brief Summary
The aim of this study is to evaluate the effectiveness and safety of the triple combination therapy of Zemidapa Tab. and Metformin in patients with type 2 diabete mellitus
Eligibility Criteria
Inclusion
- type 2 DM Patients who are receiving one of the following three therapies during which the patients are prescribed with Zemidapa Tab. for the first time at the discretion of the attending physician:
- Double combination therapy (Metformin and a DPP-4 inhibitor other than Gemigliptin)
- Triple combination therapy (Metformin, a DPP-4 inhibitor other than Gemigliptin, and a SGLT-2 inhibitor)
- Triple combination therapy (Metformin, a DPP-4 inhibitor other than Gemigliptin, and Sulfonylurea \[SU\])
- patients with HbA1c results and who signed the written consent form
Exclusion
- \- Patients contraindicated for the approved use of Zemidapa Tab. or have participated in another clinical study within 12 weeks
Key Trial Info
Start Date :
October 26 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2025
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT06495281
Start Date
October 26 2023
End Date
December 30 2025
Last Update
July 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chonnam National University Hwasun Hospital
Hwasun, Jeollanam-do, South Korea, 58128